Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627.
No abstract available

Publication types

  • Letter

MeSH terms

  • Blast Crisis* / drug therapy
  • Blast Crisis* / genetics
  • Humans
  • Mutation
  • Myeloproliferative Disorders* / drug therapy
  • Myeloproliferative Disorders* / genetics
  • Nitriles

Substances

  • ruxolitinib
  • Nitriles